Brand Intelligence Graph
Company Overview
About Muna Therapeutics
Muna Therapeutics focuses on microglial biology — the specialized immune cells of the brain — as the key to developing disease-modifying Alzheimer's therapies beyond amyloid targeting. The company uses induced pluripotent stem cell (iPSC)-derived microglia as disease models to identify and validate novel drug targets implicated by Alzheimer's genetics (TREM2, PLCG2, BIN1, APOE). This platform enables the company to study microglial dysfunction at scale and run drug screens against human-relevant cellular models.
Business Model & Competitive Advantage
Founded in Copenhagen in 2020 with co-founders from the UK Dementia Research Institute, Muna raised $75M in 2024 and is advancing multiple small molecule and antibody programs targeting TREM2 agonism and related microglial activation pathways. The company's approach differs from antibody-based TREM2 programs (Alector, Vigil Neuroscience) by pursuing oral small molecules that can penetrate the blood-brain barrier.
Competitive Landscape 2025–2026
With Alzheimer's affecting 55 million people worldwide and limited options beyond recently approved anti-amyloid antibodies, microglial biology represents one of the most genetics-validated unexplored therapeutic avenues. Muna's iPSC platform advantage enables rapid target validation cycles that outpace traditional neuroscience drug discovery timelines.
Key Differentiators
Emerging Innovator
Muna Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
NEOK Bio
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Compare Muna Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Muna Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Muna Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Muna Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →